asianprimenews
Breaking News
Breaking NewsHealthPublic Interest

Venkateshwar Hospital, Delhi successfully performs first urology procedure in north India using Medtronic Hugo™ robotic-assisted surgery system

by asianprimenews01081

• Reconstructive surgery (Pyeloplasty) performed on 25-year-old patient
• First hospital in North India to install Medtronic Hugo™ Robotic-Assisted Surgery (RAS) system

New Delhi, 09 November 2022: Venkateshwar Hospital, Delhi’s leading multi-super speciality hospital, and India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE: MDT), today announced the first urological procedure performed using the Hugo™ robotic-assisted surgery (RAS) system in north India.

The landmark procedure was performed by an expert team led by Dr (Maj. Gen) D V Singh, Director & Head, Department of Urology & Renal Transplant at Venkateshwar Hospital. The 25-year-old patient had left side PUJ (Pelvic Ureteric Junction) obstruction and a hugely enlarged kidney with compromised renal function. He underwent robotic-assisted laparoscopic reconstructive surgery (pyeloplasty) with stent, leading to successful preservation of the compromised function of his left kidney and was discharged from the hospital after two days.
Venkateshwar has also performed the first cystoprostatectomy in Asia Pacific region with the HugoTM RAS system. In this procedure, the bladder and prostate glands along with surrounding lymph nodes were removed through a minimally invasive procedure and the patient was discharged from the hospital after four days.

Mr. Kamal Solanki, CEO, Venkateshwar Hospitals said, “The introduction of robotic assisted surgery reinforces our commitment to adopt cutting-edge technologies and deliver high-quality clinical services and uncompromised patient care. The new technology complements the expertise of our clinicians and help us enhance treatment offerings to cater to the growing need of our national and international patients.”

Talking about the first surgery, Dr. Y P Bhatia, Chairman Advisory Council, Venkateshwar Hospitals said, “These procedures mark an important step forward in bringing the benefits of robotic-assisted surgery to many more patients whose health conditions require surgical treatment in specialties such as Urology, Gynecology, and General Surgery. I believe we are now entering a new phase of providing greater access, flexibility, and care to our patients.”

Dr (Maj. Gen) D V Singh, Director & Head, Department of Urology & Renal Transplant, Venkateshwar Hospital said, “The Hugo™ RAS system from Medtronic is a state-of-the-art platform in the surgical armamentarium that will empower the specialties to undertake complex procedures through minimal access with enhanced flexibility and high precision. We at Venkateshwar Hospital feel privileged in offering high quality surgical solutions to our patients especially those suffering from challenging surgical conditions.”

“Every patient in India deserves access to quality care and the benefits of minimally invasive surgery. Robotic-assisted surgery is key to making that possible. Medtronic technologies like the Hugo™ RAS system are creating a bold new era in healthcare, and we are happy to partner with Venkateshwar Hospitals to help patients when they need it the most,” said Madan Krishnan, Vice President & Managing Director, Medtronic India.

The HugoTM RAS system is a modular, multi-quadrant platform designed for a broad range of soft-tissue procedures. It combines wristed instruments, 3D visualization, and Touch Surgery™ Enterprise, a cloud-based surgical video capture and management solution, with dedicated support teams specializing in robotics program optimization, service, and training. The Hugo™ RAS system and Touch Surgery™ Enterprise are designed to bring the benefits of minimally invasive surgery — fewer complications, smaller scars, shorter hospital stays, and a faster return to normal activities1–3,† — to more patient around the world. And, in doing so, help address global inequities in access to care.

About Venkateshwar Hospitals:
Venkateshwar Hospitals is a group of Healthcare Institutions that integrates hospital care with research and education. Leading the way in the education sector for long, this is another initiative that envisions great medical facilities with uncompromised care par excellence. Venkateshwar Hospital is an establishment of Venkateshwar Group located in the heart of Dwarka Sub city in Delhi. Venkateshwar Hospital brings across a unique combination of the most qualified doctors and best-in-class technology. Till date the Hospital has successfully touched & healed millions of lives, performed over 30000+ successful surgeries, 10000+ cardiac procedures, 9000+ orthopaedic procedures and 7000+ deliveries. It is a center of excellence for Oncology, Kidney, Liver & Bone Marrow Transplant. It is poised to become the largest corporate hospital in South-West Delhi with launch of a dedicated Cancer Hospital, later this year.
About Medtronic:
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary.
For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn. For more information, visit medtronic.com/hugo.

Share

Related posts

82% of professionals in India are looking for a new job in 2025, but the search is tougher than ever

asianprimenews

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

Strong Start to FY26: Aadhar Housing Finance reports 22% Growth in AUM and 19% Rise in PAT in Q1

asianprimenews